Clinical Trial: Safety, PK and PD of FLQ-101 in Premature Neonates

U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07093255) titled 'Safety, PK and PD of FLQ-101 in Premature Neonates' on July 16.

Brief Summary: The purpose of this study is to evaluate safety and efficacy outcomes following exposure to FLQ-101.

Study Start Date: Oct. 01, 2025

Study Type: INTERVENTIONAL

Condition: Retinopathy of Prematurity (ROP)

Intervention: DRUG: FLQ-101

The invervention comprises 3 Groups:

* Group 1: Low Dose

* Group 2: Middle Dose

* Group 3: High Dose

Recruitment Status: NOT_YET_RECRUITING

Sponsor: FELIQS INC.

Published by HT Digital Content Services with permission from Health Daily Digest....